MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis

Leukemia Research

Volumn 36, Issue 1, 2012, Pages 93-97

  Ponce, Cesar Cilento ^a   Chauffaille, Maria de Lourdes F ^a   Ihara, Silvia Saiuli M ^a   Silva, Maria Regina R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Essential thrombocythemia; Fibrosis; Immunohistochemistry; Megakaryocytes; Primary myelofibrosis; Thrombopoietin receptor (MPL)

Indexed keywords

RETICULIN; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOPROLIFERATIVE NEOPLASM; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEGAKARYOCYTE; MYELOID METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 83555165116     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.024     Document Type: Article

References (22)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951, 6:372-375.
2. Foucar K. Bone marrow pathology 2001, ASCP Press (American Society for Clinical Pathology), Chicago. 2nd edition.
3. Spivak J.L., Siver R.T. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008, 112:231-239.
4. Thiele J., Kvasnicka H.M., Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 2006, 19:413-437.
5. Thiele J., Kvanicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90:1128-1132.
6. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythaemia and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
7. Kuter D., Bain B., Mufti G., Bagg A., Hasserjian R. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007, 139:351-362.
8. Zhang Y., Adachi Y., Suzuki Y., Minamino K., Iwasaki M., Hisha H., et al. Simultaneous injection of bone marrow accelerates hematopoiesis in vivo. Stem Cells 2004, 22:1256-1262.
9. Bain B.J., Clark D.M., Lampert I.A., Wilkins B.S. Bone marrow pathology 2001, Blackwell Science Ltd., London.
10. Gomori G. Silver impregnation of reticulum in paraffin sections. Am J Pathol 1937, 13:993-1001.
11. Gomori G. The effect of certain factors on the results of silver impregnation for reticulum fibers. Am J Pathol 1939, 15:493-495.
12. Buhr T., Choritz H., Georgii A. The impact of megakaryocyte proliferation of the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukaemia. Virchows Arch A Pathol Anat Histopathol 1992, 420:473-478.
13. Sakamaki S., Hirayama Y., Matsunaga T., et al. Transforming growth factor-β1 (TGF-β1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-β receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-β itself with high specificity. Blood 1999, 94(6):1961-1970.
14. Chagraoui H., Komura E., Tulliez M., Giraudier S., Vainchenker W., Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002, 100:3495-3503.
15. Bock O., Schlue J., Mengel M., Büsche G., Serinsöz E., Kreipe H. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders. J Pathol 2004, 203:609-615.
16. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3:e270.
17. Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008, 112(1):141-149.
18. van der Woude C.J., Kleibeuker J.H., Tiebosch A.T.G.M., Homan M., Beuving A., Jansen P.L.M., et al. Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins. Clin Pathol 2003, 56:699-702.
19. Tefferi A., Gilliland D.G. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle 2005, 4:1053-1056.
20. Tefferi A., Soo Y.Y., Chin Y.L. Immunohistochemical staining for megakaryocyte c-MPL may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood 2000, 96(2):771-772.
21. Mesa R.A., Hanson C.A., Chin Y.L., Soo Y.Y., Rajkumar V., Schoroeder G., et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-MPL expression in essential thrombocythaemia. Blood 2002, 99(11):4131-4137.
22. Ciurea S.O., Merchant D., Mahmud N., Ishii T., Zhao Y., Hu W., et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007, 110(3):986-993.